Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and Their Detection by the Carba NP and Modified Carbapenem Inactivation Method Tests

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Warawut LaolerdPitak Santanirand

Abstract

The purpose of the study was to determine the epidemiology of carbapenemase genes among carbapenem-resistant Enterobacteriaceae and evaluate the Carba NP and modified carbapenem inactivation method (mCIM) tests in their detection. A total of 287 nonduplicated Enterobacteriaceae isolates, which were at least resistant to one of the carbapenems, were identified and detected for carbapenemase genes by multiplex PCR covering blaKPC, blaNDM, blaVIM, blaIMP, and blaOXA-48-like. All positive genes were then sequenced. These isolates were phenotypically tested for the production of carbapenemases by mCIM and Carba NP tests to evaluate the efficacy of these methods. Seven species of carbapenem-resistant isolates mainly Klebsiella pneumoniae, Escherichia coli, and Enterobacter cloacae were detected. Of these isolates, three families of carbapenemase genes, including blaNDM (blaNDM-1, -4, -5, -9), blaOXA (blaOXA-48, -181, -232), and blaIMP-14, were found. Of these, 223 (77.70%) carried at least one of the carbapenemase genes. The blaNDM was detected in 160/223 (71.75%) isolates, of which 153/160 (95.63%) were the blaNDM-1. Three types of the blaOXA-48-like group, blaOXA-48, blaOXA-181, and blaOXA-232, were found, 91/104 (87.5%) harbored t...Continue Reading

References

Jun 22, 2007·Journal of Clinical Microbiology·K F AndersonJ B Patel
Mar 15, 2011·Diagnostic Microbiology and Infectious Disease·Laurent PoirelPatrice Nordmann
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil GuptaAlexander J Kallen
Jan 19, 2012·Antimicrobial Agents and Chemotherapy·Patrice NordmannLaurent Poirel
Apr 14, 2012·The Journal of Antimicrobial Chemotherapy·Laurent PoirelPatrice Nordmann
Aug 31, 2012·Emerging Infectious Diseases·Patrice NordmannLaurent Dortet
Feb 5, 2013·BMC Infectious Diseases·Michelle N D BalmJeanette W P Teo
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Oct 31, 2014·New Microbes and New Infections·J W P TeoK T Hsien
Dec 17, 2014·Antimicrobial Agents and Chemotherapy·Shizuo KayamaMotoyuki Sugai
Feb 24, 2015·Diagnostic Microbiology and Infectious Disease·Seok Hoon JeongWonkeun Song
May 20, 2015·Emerging Infectious Diseases·Sun Young ChoJae-Hoon Song
Feb 11, 2016·Therapeutic Advances in Infectious Disease·Georgios Meletis
Nov 24, 2016·Emerging Microbes & Infections·Shangshang QinXianju Feng
Dec 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D TammaPatricia J Simner
Feb 6, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I BitarR Migliavacca
Feb 22, 2017·International Journal of Antimicrobial Agents·Chih-Cheng LaiHung-Jen Tang
Dec 19, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Tomokazu KuchibiroYasunao Wada

❮ Previous
Next ❯

Citations

Feb 1, 2019·Clinical Microbiology Reviews·Wenjing WuZhiyong Zong
Nov 15, 2019·Clinical Microbiology Reviews·Johann D D PitoutYasufumi Matsumura
Dec 13, 2018·Frontiers in Microbiology·Shio-Shin JeanPo-Ren Hsueh
Oct 4, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Gulsen Altinkanat GelmezGuner Soyletir
Nov 23, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Arnon ChukamnerdSarunyou Chusri
Aug 2, 2019·International Journal of Antimicrobial Agents·Marissa D MalchioneJesse L Goodman
Apr 8, 2021·Expert Opinion on Pharmacotherapy·Joseph P LynchGeorge G Zhanel
Apr 30, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Samiran BandyopadhyayTriveni Dutt
May 1, 2021·Expert Review of Molecular Diagnostics·Michael R JacobsDaniel D Rhoads
Jun 7, 2021·Antimicrobial Resistance and Infection Control·Wantana PaveenkittipornNoppavan Janejai
Jun 20, 2021·Journal of Global Antimicrobial Resistance·Zhichen ZhuHong Du
Jul 2, 2021·BioMed Research International·Saba Gebremichael TekeleSamuel Kinde Birru
Jul 21, 2021·Journal of Global Antimicrobial Resistance·Ming WeiLi Gu

❮ Previous
Next ❯

Datasets Mentioned

BETA
ATCC13883

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.